Array Biopharma Inc., of Boulder, Colo., submitted two new drug applications to the FDA to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily for the treatment of those with BRAF-mutant advanced, unresectable or metastatic melanoma.
Noxxon Pharma NV, of Berlin, said the first patient had been treated in a phase I/II trial testing NOX-A12 (olaptesed pegol) in patients with metastatic colorectal and pancreatic cancer.
Anaeropharma Science Inc., of Tokyo, secured $13.2 million in new capital to fund advancement of drug candidates targeting hypoxic microenvironments of tumors by using genetically enhanced bacteria.
DUBLIN – U.K. biotech and pharmaceutical industry leaders are hopeful that their hard work in trying to ensure the U.K. maintains its position at the heart of Europe's system of drug regulation is starting to pay dividends.
Sienna Biopharmaceuticals Inc., a California-based dermatology company developing small-molecule topical therapies for people with a variety of common skin issues, is seeking gross proceeds of up to $74.8 million in an IPO.
Two groups reported that vaccinating melanoma patients with personalized, tumor-specific antigens led to progression-free survival in the majority of patients over roughly two years of follow-up. The results were reported in back-to-back papers in the July 6, 2017, issue of Nature.
Zealand Pharma A/S, of Copenhagen, started a multinational phase III trial with dasiglucagon in four countries (Austria, Germany, Canada and the U.S.).
Steadymed Ltd., of San Ramon, Calif., has submitted an FDA new drug application for its lead candidate, Trevyent (treprostinil), for the treatment of pulmonary arterial hypertension.
RSS